KR960705928A - 레트로바이러스 슈퍼항원, 슈퍼항원 펩타이드 및 그 이용방법 - Google Patents
레트로바이러스 슈퍼항원, 슈퍼항원 펩타이드 및 그 이용방법Info
- Publication number
- KR960705928A KR960705928A KR1019960702221A KR19960702221A KR960705928A KR 960705928 A KR960705928 A KR 960705928A KR 1019960702221 A KR1019960702221 A KR 1019960702221A KR 19960702221 A KR19960702221 A KR 19960702221A KR 960705928 A KR960705928 A KR 960705928A
- Authority
- KR
- South Korea
- Prior art keywords
- hiv
- nef
- superantigen
- peptide
- protein
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 13
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 title claims abstract 25
- 231100000617 superantigen Toxicity 0.000 title claims abstract 21
- 238000000034 method Methods 0.000 title claims abstract 18
- 241001430294 unidentified retrovirus Species 0.000 title claims 4
- 241000713333 Mouse mammary tumor virus Species 0.000 claims abstract description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract 3
- 239000005557 antagonist Substances 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 230000002325 super-antigenic effect Effects 0.000 claims abstract 2
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 claims description 5
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 claims description 5
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 claims description 5
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 31
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 8
- 108010033276 Peptide Fragments Proteins 0.000 claims 8
- 102000007079 Peptide Fragments Human genes 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 5
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 claims 4
- 101710197985 Probable protein Rev Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 239000003547 immunosorbent Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000007790 solid phase Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241000246358 Thymus Species 0.000 claims 1
- 235000007303 Thymus vulgaris Nutrition 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000001585 thymus vulgaris Substances 0.000 claims 1
- 241000713800 Feline immunodeficiency virus Species 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101100369989 Mus musculus Tnfaip3 gene Proteins 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
- C12N2740/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
Abstract
본 발명은 신규한 슈퍼항원 단백질과 펩타이드 및 이들 슈퍼항원들의 이용방법에 관계한다. 더욱 상세하게, 에시된 슈퍼항원 단백질 및 펩타이드 길항제 및 작동제들은 마우스 유방암 바이러스(MMTV), 고양이 면역결핍 바이러스(FIV) 및 인체 면역결핍 바이러스(HIV-1)로부터 분리된 것들이다. 상기 단백질 및 펩타이들은 슈퍼항원에 결합하는 항체의 생산, 정제 및 검출에 이용될 수도 있다. 이들 슈퍼항원들 및 이들과 동등한 펩타이드들은 진단 및 치료 수단으로 이용될 수 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 마우스 A20 세포들에 대한 MMTV ORF 펩타이드들의 경쟁적 결합을 도시한 것이다. 제 2도는 FIV ORF 4 펩타이드 면역친화도 컬럼을 이용하여 정제된 항-펩타이드 반응성 항체들에 의한 FIV 중화를 도시한 것이다. 제 3도는 감염후 (pi) 서로 다른 시간대에 취출한 FIV(Petaluma 균주)감염된 고양이로붙의 풀링된 혈청에 대한 상이한 FIV ORF 4 펩타이드들의 ELISA 반응성을 도시한 것이다.
Claims (23)
- 포유동물에 레트로바이러스 슈퍼항원, 또는 슈퍼항원 특성을 갖는 그의 펩타이드 단편을 포함하는 유효량의 제약학적 조성물을 투여하는 단계를 포함하는 동물에 있어 면역반응을 자극하는 방법.
- 제 1항에 있어서, 상기 슈퍼항원이 MMTV 3' LTR 슈퍼항원 또는 그의 펩타이드 단편인 방법.
- 제 2항에 있어서, 상기 슈퍼항원 펩타이드가 MMTV ORF(76-119)로 지정된 펩타이드를 필수적으로 포함하는 방법.
- 제 1항에 있어서, 상기 슈퍼항원이 FIV 3' LTR ORF 4 단백질 또는 그의 슈퍼항원 펩타이드 단편을 포함하는 방법.
- 제 4항에 있어서, 상기 슈퍼항원 펩타이드가 FIV ORF 4(1-30) 및 FIV ORF 4(21-55)로 지정된 펩타이드들로 구성되는 군으로부터 선택된 펩타이드를 필수적으로 포함하는 방법.
- 제 1항에 있어서, 상기 슈퍼항원이 HIV 3' LTR 슈퍼항원 또는 그의 펩타이드 단편인 방법.
- 제 6항에 있어서, 상기 슈퍼항원이 HIV-1 NeF 단백질인 방법.
- 제 6항에 있어서, 상기 슈퍼항원이 펩타이드가 HIV-1 NeF(1-38) 및 HIV-1 NeF(123-160)로 지정된 펩타이드들로 구성되는 군으로부터 선택된 펩타이드를 필수적으로 포함하는 방법.
- 레트로바이러스 슈퍼항원 단백질과 반응하는 항체를 포함할 것으로 의심되는 생물학적 시료를 슈퍼항원 단백질 또는 상기 슈퍼항원 단백질의 펩타이드 단편과 접촉시켜 면역복합체를 형성시키는 단계와 상기 면역복합체의 존재르 검출함으로써 상기 시료내의 상기 항체의 존재를 검출하는 단계를 포함하는 레트로바이러스 슈퍼항원 단백질과 반응하는 항체의 검출방법.
- 제 9항에 있어서, 상기 방법이 다음의 단계를 포함하는 방법 : ⒜ MMTV ORF(76-119), FIV ORF4(1-30), FIV ORF4(21-55), HIV-1 NeF(1-38), HIV-1 NeF(31-65), HIV-1 NeF(62-99), HIV-1 NeF(93-132), HIV-1 NeF(123-160), HIV-1 NeF(156-186), 및 HIV-1 NeF(182-206)로 지정된 펩타이드들로 구성된 군으로부터 선택된 펩타이드가 부착되는 고체상을 포함하는 면역흡착제를 시험 대상 생물학적 시료와 함께, 시료내의 모든 반응성 항체들이 면역흡착제에 결합하도록 하는 조건하에서 항온배양함으로써, 상기 펩타이드 단편들이 상기 고체상에 부착된 항원-항체 복합체의 생성을 유도하며 면역흡착-항체 복합체를 수득하는 단계; ⒝ 시료로부터 면역흡착제를 분리시키는 단계; 및 ⒞ 항체가 면역흡착제에 결합되었다면 시료내에 항-슈퍼항원 항체들의 표지로 판정하는 단계.
- 레트로바이러스의 3'LTR 서열에 의해 코드화된 아미노산 서열을 필수적으로 포함하는 정제 및 분리된 슈퍼항원 단백질 또는 펩타이드.
- 제 11항에 있어서, 상기 펩타이드가 MMTV ORF(76-119), FIV ORF4(1-30), FIV ORF4(21-55), HIV-1 NeF(1-38), HIV-1 NeF(123-160)으로 구성된 군으로부터 선택된 펩타이드를 필수적으로 포함하는 슈퍼항원.
- 제 11항의 슈퍼항원 단백질 또는 펩타이드를 코드화하는 뉴클레오티드 서열을 포함하는 분리된 폴리뉴클레오티드.
- 레트로바이러스의 3'LTR 서열에 의해 코드화된 슈퍼항원 단백질 또는 그의 펩타이드 단편에 특이적으로 결합하는 분리된 항체.
- 제 14항에 있어서, 상기 항체가 HIV-1 NeF 단백질 또는 그의 펩타이드 단편에 특이적으로 결합하는 항체.
- 제 15항에 있어서, HIV-1 NeF(1-38), HIV-1 NeF(31-65), HIV-1 NeF(62-99), HIV-1 NeF(93-132), HIV-1 NeF(123-160), HIV-1 NeF(156-186), 및 HIV-1 NeF(182-206)로 지정된 HIV-1 NeF 펩타이드들로 구성된 군으로부터 선택된 아미노산 서열에 특이적으로 결합하는 항체.
- NeF 길항제를 투여하는 과정을 포함하는 HIV-1 NeF 단백질의 효과를 억제하는 방법.
- 제 17항에 있어서, 상기 길항제가 HIV-1 NeF 단백질, 또는 그의 단편에 대한 항체; HIV-1 NeF 펩타이드에 대한 항체; HIV-1 NeF 단백질, 또는 그의 단편을 코드화하는 폴리뉴클레오티드에 대해 안티센스인 폴리 뉴클레오티드; 클래스 Ⅱ MHC 분자에 결합하지만, 이들 MHC 분자를 포함하는 세포들을 활성화하지는 않는 HIV-1 NeF 펩타이드 및 펩타이드 유사체; 및 클래스 Ⅱ MHC 분자에 결합하여 이들 분자들에 대한 HIV-1 NeF 단백질의 결합을 차단하는 항체로 구성되는 군으로부터 선택되는 방법.
- 제 18항에 있어서, 상기 HIV-1 NeF 펩타이드가 HIV-1 NeF(1-38), HIV-1 NeF(31-65), HIV-1 NeF(62-99), HIV-1 NeF(93-132), HIV-1 NeF(123-160), HIV-1 NeF(156-186), 및 HIV-1 NeF(182-206)로 지정된 HIV-1 NeF 펩타이드들로 구성된 군으로부터 선택된 아미노산 서열을 갖는 방법.
- 제약학상 허용가능한 부형제내에 HIV-1 NeF 단백질 또는 그의 단편 또는 변형체를 포함하는 면역반응 유발 조성물.
- 제 20항에 있어서, 상기 면역반응유발 조성물이 HIV-1 NeF(123-160)로 지정된 펩타이드를 포함하는 면역반응 유발 조성물.
- 동물에 레트로바이러스 슈퍼항원 또는 슈퍼항원 특성을 갖는 그의 단편 또는 변형체를 함유하는 유효량의 제약학적 조성물을 투여하는 과정을 포함하는, 동물에 있어서 특정한 Vβ 타임 T 세포 수용체를 포함하는 T 세포를 고갈 또는 불활성화하는 방법.
- 제 22항에 있어서, 상기 슈퍼항원이 HIV-1 NeF 단백질 또는 슈퍼항원 특성을 갖는 그의 단편 또는 변형체를 포함하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/145,708 US5519114A (en) | 1993-10-29 | 1993-10-29 | Retroviral superantigens, superantigen peptides, and methods of use |
| US08/145,708 | 1993-10-29 | ||
| PCT/US1994/012499 WO1995011975A2 (en) | 1993-10-29 | 1994-10-31 | Retroviral superantigens, superantigen peptides, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR960705928A true KR960705928A (ko) | 1996-11-08 |
Family
ID=22514199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960702221A KR960705928A (ko) | 1993-10-29 | 1994-10-31 | 레트로바이러스 슈퍼항원, 슈퍼항원 펩타이드 및 그 이용방법 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5519114A (ko) |
| EP (1) | EP0730650A1 (ko) |
| JP (1) | JPH09505282A (ko) |
| KR (1) | KR960705928A (ko) |
| AU (1) | AU1085595A (ko) |
| CA (1) | CA2175255A1 (ko) |
| WO (1) | WO1995011975A2 (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| AU2429397A (en) * | 1996-03-29 | 1997-10-22 | David S. Terman | Polymerized staphylococcal protein a for treatment of diseases |
| US6075119A (en) | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
| WO1999005527A2 (en) * | 1997-07-22 | 1999-02-04 | Novimmune Sa | Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| EP0893691A1 (en) * | 1997-07-23 | 1999-01-27 | Mach, Bernard François, Prof. | Methods for diagnosis and therapy of autoimmunedisease, such as insulin dependent diabetes mellitus, involving retroviral superantigens |
| US7491402B2 (en) * | 1998-12-24 | 2009-02-17 | Auckland Uniservices Limited | Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof |
| US20010008627A1 (en) * | 1999-01-22 | 2001-07-19 | Soll David R. | Hiv-encoded chemoattractant |
| US6982086B2 (en) | 2000-02-04 | 2006-01-03 | Duke University | Human immunodeficiency virus immunogenic composition |
| US20010046501A1 (en) * | 2000-03-14 | 2001-11-29 | Johnson Howard M. | Superantigen enhancement of specific immune responses |
| AU2002216481B2 (en) * | 2000-12-04 | 2008-05-01 | Auckland Uniservices Limited | Immunomodulatory constructs and their uses |
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| CN1210294C (zh) * | 2001-07-13 | 2005-07-13 | 一泰医药研究（深圳）有限公司 | 序列号21的生物活性肽 |
| NZ519371A (en) * | 2002-06-04 | 2004-11-26 | Auckland Uniservices Ltd | Immunomodulatory constructs and their uses |
| DE602004009818T2 (de) | 2003-11-05 | 2008-09-18 | Intercell Ag | Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target-antigene |
| CA2577183C (en) * | 2004-08-17 | 2014-02-18 | Institut Gustave Roussy | Mutated hiv nef for modulating immunity |
| CN117679499A (zh) | 2016-01-10 | 2024-03-12 | 尼奥克斯医疗有限公司 | 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物 |
| WO2020230142A1 (en) | 2019-05-15 | 2020-11-19 | Neotx Therapeutics Ltd. | Cancer treatment |
| US20230085724A1 (en) | 2020-03-05 | 2023-03-23 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03503639A (ja) * | 1988-04-01 | 1991-08-15 | アンステイテユ・パストウール | レトロウイルスｈｉｖのペプチドｐｆ１０〜ｐｆ１９、該ペプチドの合成方法、特に診断用としてのその使用 |
| US5221610A (en) * | 1988-05-26 | 1993-06-22 | Institut Pasteur | Diagnostic method and composition for early detection of HIV infection |
| FR2650954B1 (fr) * | 1989-08-18 | 1992-02-28 | Pasteur Institut | Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida |
-
1993
- 1993-10-29 US US08/145,708 patent/US5519114A/en not_active Expired - Fee Related
-
1994
- 1994-10-31 US US08/331,454 patent/US5968514A/en not_active Expired - Fee Related
- 1994-10-31 JP JP7512888A patent/JPH09505282A/ja active Pending
- 1994-10-31 EP EP95901727A patent/EP0730650A1/en not_active Withdrawn
- 1994-10-31 WO PCT/US1994/012499 patent/WO1995011975A2/en not_active Application Discontinuation
- 1994-10-31 KR KR1019960702221A patent/KR960705928A/ko not_active Application Discontinuation
- 1994-10-31 AU AU10855/95A patent/AU1085595A/en not_active Abandoned
- 1994-10-31 CA CA002175255A patent/CA2175255A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2175255A1 (en) | 1995-05-04 |
| JPH09505282A (ja) | 1997-05-27 |
| WO1995011975A2 (en) | 1995-05-04 |
| WO1995011975A3 (en) | 1995-07-27 |
| US5968514A (en) | 1999-10-19 |
| EP0730650A1 (en) | 1996-09-11 |
| US5519114A (en) | 1996-05-21 |
| AU1085595A (en) | 1995-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960705928A (ko) | 레트로바이러스 슈퍼항원, 슈퍼항원 펩타이드 및 그 이용방법 | |
| Fu et al. | Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. | |
| JP2675009B2 (ja) | 改良ペプチド組成物およびｈｉｖに対する抗体の検出方法 | |
| Liu et al. | Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors | |
| Stoiber et al. | Interaction of several complement proteins with gp120 and gp41, the two envelope gycoproteins of HIV-1 | |
| RU2225721C2 (ru) | Способы и композиции для модуляции взаимодействия между apj-рецептором и вирусом иммунодефицита человека (вич) | |
| Casey et al. | Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24 | |
| US5834429A (en) | Small peptides which inhibit binding to T-4 receptors and act as immunogens | |
| JP3356280B2 (ja) | 哺乳動物免疫不全ウイルスの検出 | |
| EP0641357B1 (en) | Hiv protein epitopes immunologically homologous to hla | |
| JP3533214B2 (ja) | Ｈｉｖ抗体検出用の合成ペプチドとその混合物 | |
| Hussain et al. | Antigenic mapping of the envelope proteins of equine infectious anemia virus: identification of a neutralization domain and a conserved region on glycoprotein 90 | |
| EP1417222B1 (en) | Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope | |
| FI101797B (fi) | STLV-III-virukseen liittyvät polypeptidit, diagnostiset järjestelmät j a määritysmenetelmät | |
| Mygland et al. | Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis | |
| JPH01224397A (ja) | Ｈｉｖ抗体を検出するための合成ペプチド及びその混合物 | |
| Marty et al. | Transmembrane orientation of the N-terminal and C-terminal ends of the ryanodine receptor in the sarcoplasmic reticulum of rabbit skeletal muscle | |
| Mathiesen et al. | Analysis of a subclass-restricted HIV-1 gp41 epitope by omission peptides. | |
| Neurath et al. | Rapid Prescreening for Antiviral Agents against HIV-1 Based on Their Inhibitory Activity in Site-Directed Immunoassays. I. The V3 Loop of gp 120 as Target | |
| Auwanit et al. | Unusually high seroprevalence of Borna disease virus in clade E human immunodeficiency virus type 1-infected patients with sexually transmitted diseases in Thailand | |
| HAIST et al. | Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans | |
| AU636145B2 (en) | New human parvovirus peptides with disulfide bridge for immunization or diagnosis | |
| KR930008448B1 (ko) | T-4수용체에 대한 결합을 억제하며, 면역원으로서 작용하는 소형 펩티드 | |
| Cotton et al. | Design and synthesis of a highly immunogenic, discontinuous epitope of HIV-1 gp120 which binds to CD4+ ve transfected cells | |
| JPS63264600A (ja) | ウシ白血病ウイルスに対する感染防御抗体を誘導するペプチド分画と、この分画を得る方法と、この分画の遺伝暗号配列と、この分画から製造されるワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |